ENVALITH
株式会社資生堂 logo

Shiseido Company, Limited

4911・Prime Market・Chemicals

Official website
株式会社資生堂 logo
Shiseido Company, Limited4911

Business

Shiseido Company, Limited has a history of over 150 years since its founding in 1872, and is Japan's largest cosmetics manufacturer, comprising the company itself, 64 subsidiaries, and 3 affiliated companies. Centered on the manufacture and sale of cosmetics, cosmetic tools, beauty foods, and pharmaceuticals, it operates globally across six segments: Japan, China, Travel Retail, Asia Pacific, Americas, and Europe. Of its net sales of ¥969,992 million, the China & Travel Retail Business accounts for 35.3% and the Japan Business for 30.4%, and the company holds a diverse brand portfolio including SHISEIDO, Clé de Peau Beauté, ELIXIR, NARS, and Drunk Elephant. Its main customers are general consumers around the world and purchasers through distribution channels such as duty-free stores, department stores, and e-commerce.

Business Model

Building on dermatological science and formulation technology generated through in-house R&D (R&D expenses of ¥27.1 billion, 2.8% of net sales), the company focuses selection and concentration on prestige brands such as "SHISEIDO" and "Clé de Peau Beauté." It sells globally through multiple channels including department stores, specialty stores, e-commerce, and duty-free stores (Travel Retail), securing profitability through a premium product mix with high profit margins. While the company-wide core operating profit margin is 4.6% (FY2025), high-profitability segments drive earnings, with the China & Travel Retail Business at 18.7% and the Japan Business at 13.1%.

Company Strengths

Deploys research bases in the US, France, and China centered on the Shiseido Global Innovation Center. Won the Best Poster Award at the 35th IFSCC (International Federation of Societies of Cosmetic Chemists) Congress Cannes 2025 and the 1st Prize for Oral Presentation at the 17th ASCS (Asian Societies of Cosmetic Scientists) Congress Manila 2025. Continues to generate world-first findings through joint research with institutions such as Massachusetts General Hospital, Tohoku University, and the University of Tokyo.

The China & Travel Retail Business, accounting for 35.3% of consolidated net sales, achieved a core operating margin of 18.7% (¥64,525 million) in FY2025. Focus prestige brands such as Clé de Peau Beauté and NARS grew significantly in China e-commerce (Double Eleven), and combined with the effects of structural reforms to reduce fixed costs, the segment has become the largest contributor to group profit.

Based on "Mirai Shift NIPPON 2025," fixed cost reductions and brand selection and concentration significantly improved the Japan Business's core operating margin from 8.8% in the previous fiscal year to 13.1% in FY2025. Core operating profit increased 50.6% year on year, from ¥25,879 million to ¥38,972 million. Inbound demand, supported by a record-high number of foreign visitors to Japan, continues to contribute as well.

ENVALITH's Perspective

Core operating profit of ¥13,029 million for 1Q FY2026 represents 18.9% of the full-year forecast of ¥69,000 million, and net income attributable to owners of the parent of ¥8,371 million represents 19.9% of the full-year forecast of ¥42,000 million. Even accounting for seasonality, the progress rate is favorable. The real-term change in net sales was -2.7%, a slight decline when excluding foreign exchange and business transfer effects, but the quality of profit improvement is high, confirming the emergence of structural reform effects. No revision was made to the full-year earnings forecast.

The Europe Business posted a core operating loss of ¥1,637 million (worsening from a loss of ¥422 million in the same period of the previous year), while the Japan Business also saw sales decline to ¥71,218 million (down 4.0% year on year). Meanwhile, the Americas Business achieved core operating profit of ¥329 million, turning profitable from a loss of ¥1,853 million in the same period of the previous year, with the Drunk Elephant turnaround progressing. As an external factor, the weaker yen (positive foreign currency translation adjustment) is boosting comprehensive income, but the recovery of sales on a real-term basis remains a challenge.

As a subsequent event, a decision was made to close the Shiseido Taiwan Hsinchu plant (which produces skincare products, etc.) and transfer production domestically. Total closure costs are expected to be approximately ¥3.5 billion (non-recurring item), of which approximately ¥2.0 billion for the current fiscal year has already been factored into the full-year earnings forecast, with an additional approximately ¥1.5 billion expected to arise in the following fiscal year. This is a concrete embodiment of the "Evolution of Global Operations" initiative under the "2030 Mid-Term Management Strategy," aimed at improving global plant utilization rates and cost efficiency, and is judged to contribute to medium- to long-term profit improvement.

Growth Strategy

Under the 2030 mid-term strategy, the company is advancing brand value maximization, evolution of global operations, and sustainable value creation

Fundamental overhaul of the cost structure through fixed cost reduction, unprofitable business restructuring, and organizational streamlining. Effects are becoming visible with the core operating profit margin improving to 5.6% in Q1 FY2026 (versus 3.6% in the same period of the prior year). Reduction in head office expenses (from ¥19,367 million in the same period of the prior year to ¥15,598 million in the current period) is driving profit improvement.

Strategic investment concentrated on focus brands such as "SHISEIDO," "Clé de Peau Beauté," and "NARS." The China & Travel Retail Business achieved a core operating profit margin of 19.8%, with the effects of concentration on high-value-added brands reflected in the numbers.

Shiseido Taiwan's Hsinchu plant is scheduled to end production in Q1 FY2027 and close in the second half of the year, with manufacturing transferred to domestic sites such as the Nasu plant. This aims to improve global plant utilization rates and cost efficiency, while Shiseido Taiwan concentrates management resources on the local distribution business. Closure costs of approximately ¥3.5 billion have already been factored into the earnings forecast.

The Americas Business turned profitable in Q1 FY2026 with core operating profit of ¥329 million, versus a core operating loss of ¥1,853 million in the same period of the prior year. A real sales change rate of up 5.1% confirmed actual recovery. Structural reform of Drunk Elephant and strengthened strategic investment in core brands are beginning to bear fruit.

The Europe Business posted a core operating loss of ¥1,637 million in Q1 FY2026, worsening from a loss of ¥422 million in the same period of the prior year. Growth driven by new fragrance product launches such as "Zadig&Voltaire" and "narciso rodriguez," together with the recovery of Prestige Skincare, is key to improving profitability. As an external factor, the weaker European currencies (real change rate of down 9.9%) are acting as a headwind.

Last updated: July 17, 2026